Lyu, Jiao
Zhang, Qi
Chen, Chunli
Xu, Yu
Ji, Xunda
Zhao, Peiquan http://orcid.org/0000-0002-5092-9550
Funding for this research was provided by:
National Natural Science Foundation Project of China (81470642)
National Natural Science Foundation Project of China (81800837, 81770964)
Article History
Received: 21 September 2018
Accepted: 8 February 2019
First Online: 26 February 2019
Ethics approval and consent to participate
: Study protocols were in accordance with the tenets of Declaration of Helsinki and approved by the hospital ethics committee (Ethics Committee of Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine). The study and off-label use of Ranibizumab were certified by Ethics Committee of Xin hua Hospital and informed consent to participate was exempted due to retrospective nature of the study (Approval No. XHEC-D-2018-028).Written informed consent for off-label IVR treatment for ROP was obtained from legal guardians of all patients after detailed counseling regarding the potential benefits (possibly, quick regression after single injection, anterior progression of retinal vascularization, preservation of peripheral visual field) and risks (possibly, infection, hemorrhage, fibrosis, retreatment) of the treatment.
: Not applicable.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.